Lumasiran clinical trials
Also written ALN-GO1 and OXLUMO.
How each study uses lumasiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lumasiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Nov 2020 · OXLUMO · NDA 214103 (FDA, Drugs@FDA)
- European Union
- 19 Nov 2020 · Oxlumo · EMEA/H/C/005040 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Alnylam Pharmaceuticals (6) · Charite University, Berlin, Germany (1)
Studies
Open first, then newest update. How each study uses lumasiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Lumasiran in Hyperoxalaemic Patients on HaemodialysisRecruitingPhase 2Charite University, Berlin, GermanyNCT06225544Written as LumasiranHow we know
- A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedPhase 3Alnylam PharmaceuticalsNCT04152200Written as LumasiranHow we know
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedPhase 3Alnylam PharmaceuticalsNCT03905694Written as LumasiranHow we know
- A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1CompletedPhase 3Alnylam PharmaceuticalsNCT03681184Written as LumasiranHow we know
- A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate LevelsTerminatedPhase 2Alnylam PharmaceuticalsNCT05161936Written as LumasiranHow we know
- An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1CompletedPhase 2Alnylam PharmaceuticalsNCT03350451Written as LumasiranHow we know
- Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1CompletedPhase 1/2Alnylam PharmaceuticalsNCT02706886Written as LumasiranHow we know
Codes
What other systems call lumasiran · ClinicalTrials.gg INT001601
- MeSH (NLM) C000716350lumasiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RZT8C352O1LUMASIRANConfirmed FDA, NLM, Wikidata
- RxNorm 2467140One source FDA
- Wikidata Q100692768lumasiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170137LumasiranOne source FDA
- DrugBank DB15935One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716350 | lumasiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RZT8C352O1 | LUMASIRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2467140 | — | One source FDA |
| Wikidata | Q100692768 | lumasiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170137 | Lumasiran | One source FDA |
| DrugBank | DB15935 | — | One source Wikidata |
Also registered as lumasiran sodium (UNII 67P6XH37HD · RxNorm 2467161).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.